Health Care Modeling For Forecasting Quality And Cost Outcomes Also Addresses Clinical Trial Needs
Archimedes, Inc.
, a San Francisco-based healthcare modeling company, and the
Robert Wood Johnson Foundation
announced that the US Department of Health and Human Services (HHS) has contracted with Archimedes to provide HHS agencies with direct access to the
ARCHeS Innovator
. The Archimedes Model, developed initially with support from Kaiser Permanente, is an advanced mathematical modeling tool available to answer complex questions on health and health care. Under this contract, HHS will make a new web-based interface called the Archimedes Healthcare Simulator (ARCHeS) available to its agencies, including the Centers for Medicare and Medicaid Services, the Centers for Disease Control and Prevention, the Agency for Healthcare Research and Quality, the National Heart, Lung & Blood Institute and the Food & Drug Administration. For clinical trials, the modeling tool will users to run clinically realistic virtual trials on any population and to help with comparative effectiveness research, and clinical trial design and portfolio management.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
